TW202339764A - 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 - Google Patents
19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 Download PDFInfo
- Publication number
- TW202339764A TW202339764A TW111150395A TW111150395A TW202339764A TW 202339764 A TW202339764 A TW 202339764A TW 111150395 A TW111150395 A TW 111150395A TW 111150395 A TW111150395 A TW 111150395A TW 202339764 A TW202339764 A TW 202339764A
- Authority
- TW
- Taiwan
- Prior art keywords
- sleep
- compound
- individual
- administered
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558703P | 2017-09-14 | 2017-09-14 | |
| US62/558,703 | 2017-09-14 | ||
| US201862624680P | 2018-01-31 | 2018-01-31 | |
| US201862624678P | 2018-01-31 | 2018-01-31 | |
| US62/624,678 | 2018-01-31 | ||
| US62/624,680 | 2018-01-31 | ||
| US201862653189P | 2018-04-05 | 2018-04-05 | |
| US62/653,189 | 2018-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202339764A true TW202339764A (zh) | 2023-10-16 |
Family
ID=65723895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107132510A TW201919642A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
| TW111150395A TW202339764A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107132510A TW201919642A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220110949A1 (enExample) |
| EP (2) | EP4218767A1 (enExample) |
| JP (3) | JP2020534270A (enExample) |
| AU (2) | AU2018334214A1 (enExample) |
| CA (1) | CA3075872A1 (enExample) |
| IL (2) | IL303083A (enExample) |
| MX (3) | MX2020002889A (enExample) |
| TW (2) | TW201919642A (enExample) |
| WO (1) | WO2019055764A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60343B1 (sr) | 2014-11-27 | 2020-07-31 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114761019A (zh) * | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362543B (es) * | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| EP4275748A3 (en) * | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JOP20190022B1 (ar) * | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
-
2018
- 2018-09-14 AU AU2018334214A patent/AU2018334214A1/en not_active Abandoned
- 2018-09-14 WO PCT/US2018/051048 patent/WO2019055764A1/en not_active Ceased
- 2018-09-14 MX MX2020002889A patent/MX2020002889A/es unknown
- 2018-09-14 IL IL303083A patent/IL303083A/en unknown
- 2018-09-14 TW TW107132510A patent/TW201919642A/zh unknown
- 2018-09-14 EP EP23150618.9A patent/EP4218767A1/en active Pending
- 2018-09-14 US US16/647,203 patent/US20220110949A1/en not_active Abandoned
- 2018-09-14 TW TW111150395A patent/TW202339764A/zh unknown
- 2018-09-14 EP EP18786464.0A patent/EP3681510A1/en not_active Withdrawn
- 2018-09-14 JP JP2020514950A patent/JP2020534270A/ja active Pending
- 2018-09-14 CA CA3075872A patent/CA3075872A1/en active Pending
-
2020
- 2020-03-08 IL IL273126A patent/IL273126A/en unknown
- 2020-03-13 MX MX2023010063A patent/MX2023010063A/es unknown
- 2020-03-13 MX MX2023010064A patent/MX2023010064A/es unknown
-
2023
- 2023-01-24 JP JP2023008782A patent/JP2023038310A/ja active Pending
- 2023-03-01 US US18/176,571 patent/US20230201224A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091642A patent/JP2024107137A/ja active Pending
- 2024-08-07 AU AU2024205601A patent/AU2024205601A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018334214A1 (en) | 2020-03-26 |
| JP2020534270A (ja) | 2020-11-26 |
| MX2023010064A (es) | 2023-09-06 |
| IL303083A (en) | 2023-07-01 |
| TW201919642A (zh) | 2019-06-01 |
| JP2023038310A (ja) | 2023-03-16 |
| AU2024205601A1 (en) | 2024-08-29 |
| WO2019055764A1 (en) | 2019-03-21 |
| JP2024107137A (ja) | 2024-08-08 |
| MX2020002889A (es) | 2020-10-01 |
| EP4218767A1 (en) | 2023-08-02 |
| IL273126A (en) | 2020-04-30 |
| CA3075872A1 (en) | 2019-03-21 |
| MX2023010063A (es) | 2023-09-06 |
| EP3681510A1 (en) | 2020-07-22 |
| US20220110949A1 (en) | 2022-04-14 |
| US20230201224A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230201224A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| JP2025169279A (ja) | 睡眠時無呼吸を治療する方法及び組成物 | |
| JP2025163125A (ja) | Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法 | |
| TW202133863A (zh) | １９—ｎｏｒ—ｃ３，３—二取代—ｃ２１—ｎ—吡唑基類固醇及使用其之方法 | |
| JP7705348B2 (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| TW202341995A (zh) | 用於治療cns相關病症之神經活性類固醇 | |
| KR20230018384A (ko) | T-형 칼슘 채널 조정제의 사용 방법 | |
| CN114786660A (zh) | 使用mtorc1调节剂的治疗方法 | |
| US20250387414A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| HK40096830A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20220305012A1 (en) | Lemborexant for treating sleep issues | |
| RU2844395C2 (ru) | Лемборексант для лечения проблем со сном | |
| AU2024238367A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| EP3989976A1 (en) | Lemborexant for treating sleep issues | |
| KR20250165616A (ko) | 고함량 단일 투여 단위 제형 및 이의 사용 방법 | |
| WO2020263331A1 (en) | Lemborexant for treating sleep issues | |
| TW202508553A (zh) | 用於預防、減緩或治療睡眠障礙及／或與睡眠障礙相關之疾病的方法 | |
| JP2025116005A (ja) | 睡眠問題の治療のためのレンボレキサント | |
| TW202320783A (zh) | 治療與神經系統變性疾病相關的不規律睡眠覺醒節律紊亂和晝夜節律性睡眠障礙之方法 | |
| Vinogradov et al. | Insomnia and Sleep-Related Breathing Disorders: New Risk Factors for Ischemic Stroke | |
| Parkes et al. | Disorders of Sleep and Wakefulness | |
| HK1145282B (en) | Treatment of sleep disorders | |
| TW200800160A (en) | Prophylactic or therapeutic agent for sleep disorder |